The Ontario Hereditary Cancer Research Network's (OHCRN) participant portal is now open and Ontarians at risk of hereditary cancers are invited to register.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD(TM) CorEvitas(TM) Myasthenia Gravis (MG) Registry. This ...

The RARE Summit 2025 proved its value to the rare disease community with a packed day of events, talks and opportunities to make connections, exchange ideas and openly debate possibilities.

Nobody really knows how to speak to the future in a way that it will hear.